Juno Therapeutics’ stock surges in debut
December 19, 2014 at 13:11 PM EST
Juno Therapeutics stock surges in debut above IPO price, valuing the cancer drug developer at more than $3 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.